Allergan, the pharmaceutical company headquartered in Dublin, Ireland, has acquired US company Zeltiq Aesthetics, the maker of the body contouring treatment CoolSculpting.
The deal, worth approximately $2.4bn, is said to make body contouring Allergan’s ‘third pillar’, after facial aesthetics and plastic & regenerative medicine.
Bill Meury, Chief Commercial Officer of Allergan, said: "We are thrilled to complete the acquisition of Zeltiq, which immediately expands our world-class global aesthetic business into the highly-complementary and fast-growing body contouring segment.”
CoolSculpting System is marketed in more than 80 countries, with new market expansion planned for 2017 and 2018.
The treatment works by cooling targeted fat cells to induce their natural breakdown and elimination from the body, without affecting surrounding tissue.
